Other Events ·
Neumora Therapeutics, Inc. reported favorable pre-clinical toxicology results for NMRA-215, an oral NLRP3 inhibitor…
NMRANeumora Therapeutics, Inc.
Neumora Therapeutics, Inc. reported favorable pre-clinical toxicology results for NMRA-215, an oral NLRP3 inhibitor for obesity and cardiometabolic disease. Following a for-cause audit that cleared discrepancies in a previous study, a repeat 13-week rat toxicology study in 162 animals showed no unexpected in-life adverse findings. The company plans to submit an IND application in the fourth quarter of 2026 and initiate a Phase 1 study by the end of 2026. Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapies for brain diseases and underserved, prevalent diseases.